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Ocular inﬂammation is a signiﬁcant cause of ocular morbidity and visual impairment. Topical, periocular,
intraocular, and systemic corticosteroids are highly effective for treating appropriate forms of ocular
inﬂammation. However, their use may be constrained by local and/or systemic side effects, especially if
long-term therapy is required. As a result, immunosuppressive agents increasingly have been used to
manage ocular inﬂammation alongside or in place of corticosteroids. The four categories of agents used
today are antimetabolites [primarily methotrexate, mycophenolate mofetil (MMF), and azathioprine]; T-
cell inhibitors (usually cyclosporine, less often tacrolimus or sirolimus); alkylating agents (cyclophos-
phamide and chlorambucil); and biologic agents [tumor necrosis factor (TNF) inhibitors, lymphocyte
inhibitors, and interleukin inhibitors]. The primary goals of immunosuppressive therapy are (1) to
control inﬂammation when corticosteroids fail to do so; (2) to prevent corticosteroid-induced toxicity
when the necessary corticosteroid dosage exceeds the desired or safe level (corticosteroid sparing); and
(3) to treat speciﬁc high-risk uveitis syndromes known to respond poorly to corticosteroids alone.
Growing evidence shows the effectiveness of immunosuppressive drugs in achieving these goals, as well
as improved visual function, prevention of ocular complications, and in some cases even disease
remission. However, these agents also have side effects, which must be considered in each patient's
management. In this report, we summarize the effectiveness and safety of immunosuppressive drug
therapy utilized in the treatment of ocular inﬂammatory diseases.
Copyright © 2015, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Effectiveness of immunosuppressive agents
Ocular inﬂammation can produce considerable ocular morbidity
and visual impairment. Although topical, periocular, intraocular,
and systemic corticosteroids may be highly effective, their use may
be limited in some patients due to ocular and/or systemic side ef-
fects. Thus, immunosuppressive agents are increasingly used to
manage ocular inﬂammation alongside or in place of corticoste-
roids. The categories of immunosuppressive agents are antime-
tabolites (e.g., methotrexate, MMF, and azathioprine); T-cell
inhibitors (e.g., cyclosporine and tacrolimus); alkylating agents
(e.g., cyclophosphamide and chlorambucil); and biologic agentse no conﬂicts of interest.
unology, The Wilmer Eye
North Wolfe Street, Woods
ciety of Taiwan. Published by Else(e.g., TNF inhibitors, lymphocyte inhibitors, and interleukin in-
hibitors; Table 1).
Immunosuppressive therapy is primarily used in the following
cases: (1) to control inﬂammation when corticosteroids fail to do
so; (2) to prevent corticosteroid-induced toxicity (corticosteroid
sparing); and (3) to treat high-risk uveitis syndromes unresponsive
to corticosteroids alone. Growing evidence shows the effectiveness
of immunosuppressive drugs in achieving these goals, as well as
producing desirable clinical outcomes such as improved visual
function, prevention of ocular complications, and in some cases
even disease remission.
1.1. Effectiveness: Disease control, corticosteroid reduction, and
treatment of speciﬁc diseases
Although the number of randomized clinical trials for uveitis
treatments is increasing, the majority of data regarding the effec-
tiveness of immunosuppressive drug therapy in treating ocularvier Taiwan LLC. All rights reserved.
Table 1
Classes of immunosuppressive drugs used in ocular inﬂammation.
Class Generic name Trade name
Antimetabolites Azathioprine Imuran
Methotrexate Rheumatrex
Mycophenolate mofetil CellCept
T-cell/calcineurin inhibitors Cyclosporine Sandimmune
Neoral
Gengraf
Tacrolimus Prograf
Voclosporina Luveniqa
Alkylating agents Cyclophosphamide Cytoxan
Chlorambucil Leukeran
Biologics
TNF inhibitors Etanercept Enbrel
Inﬂiximab REMICADE
Adalimumab Humira
Lymphocyte inhibitors Rituximab RITUXAN
Abatacept ORENCIA
Interferons Interferon alpha-2a Roferon-A
IL-1 antagonist Anakinra Kineret
IL-2 antagonist Daclizumab a Zenapax a
IL ¼ interleukin; TNF ¼ tumor necrosis factor.
a Not on the market.
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These include uncontrolled case series and cohort studies in which
more robust statistical techniques such as longitudinal data anal-
ysis and time-to-event data (cumulative incidence data) may be
used. For example, the Systemic Immunosuppressive Therapy for
Eye Diseases Cohort Study (SITE) is a large retrospective cohort
study of 7957 patients with noninfectious ocular inﬂammatory
diseases treated at ﬁve tertiary-care centers from 1979 to 2005. This
study provided data on the demographic characteristics, clinical
course, treatment outcomes, side effects, discontinuation rates, and
overall and cancer-associated mortality due to immunosuppressive
therapy in these patients.1
Reported outcomes typically used for measuring treatment ef-
ﬁcacy and effectiveness are disease control and reduction of corti-
costeroid dosage to desirable levels (“corticosteroid-sparing”
effect).2 Disease control in uveitis (inactive anterior uveitis) may be
deﬁned as rare cells or less in the anterior chamber; grade 0 vitre-
ous cells (not including inactive cells seen in the formed vitreous)
and grade 0 vitreous haze; and absence of active chorioretinal le-
sions, depending on the anatomic categorization of the uveitis.2
Although there are some published studies describing speciﬁc pa-
rameters for disease control in other ocular inﬂammatory dis-
eases,3,4 many retrospective studies use the medical judgment of
the physician to deﬁne disease control. Occasionally, reproduc-
ibility of disease control is required as part of the treatment-relatedTable 2
Effectiveness: Percentage of patients achieving disease control, corticosteroid-sparing su
Medication % Disease control % Corticosteroid sparin
Methotrexate 66 6 58 6
Azathioprine 62 5
Mycophenolate mofetil 73% by 1 y 7 55e82 7,10
Cyclosporine 50 8 36 8
Tacrolimus 62 8
Cyclophosphamide 76% by 1 y 9 61% by 1 y 9
Chlorambucil
TNF inhibitors
MMP ¼ mucous membrane pemphigoid; PY ¼ person-year.outcome, as is the case in published SITE data in which disease
control requires inactivity of inﬂammation spanning at least two
visits spaced 28 days apart. The end point of corticosteroid-sparing
success includes the control of the ocular inﬂammation disease
coupled with the ability to taper the systemic corticosteroid to a
level acceptable for long-term use. In the past, that level had been
thought to be  10 mg of oral prednisone daily, although more
recently a cutoff of  7.5 mg of prednisone daily is typically used in
most cases. Table 2 summarizes the control of ocular inﬂammation
and corticosteroid-sparing success for speciﬁc immunosuppressive
drug therapies as reported by the SITE Cohort Study. These studies
are summarized comparatively because the same end point was
utilized in each report focusing on speciﬁc immunosuppressive
drugs.
Regarding antimetabolites, azathioprine successfully controlled
inﬂammatory disease in 62% of patients5; methotrexate in 66% of
patients6; and MMF in 73% of patients.7 The T-cell inhibitors
cyclosporine and tacrolimus achieved disease control in 52% and
62% of patients, respectively8; and the alkylating agent cyclo-
phosphamide controlled disease in 76% of patients.9 Corticosteroid-
sparing success was reported as 47%, 58%, and 55e82% for azathi-
oprine, methotrexate, and MMF, respectively.5e7,10 Corticosteroid-
sparing success for mycophenolate was different in the Daniel
et al7 and Thorne et al10 papers because in the case of the Thorne
et al10 article, success measured over two visits was not required.
Although this article10 and another from the Johns Hopkins
cohort11 suggest that corticosteroid-sparing success may occur
more frequently10 and more rapidly11 with MMF than with the
other antimetabolites, a multicenter, randomized, observer-
masked clinical trial of 80 patients comparing methotrexate with
mycophenolate therapy for uveitis failed to demonstrate a statis-
tically signiﬁcant difference between the two therapies.12
The corticosteroid-sparing success of cyclosporine was lower
(36%) and that of cyclophosphamidewas similar (61%) to the results
observed with the antimetabolites in the SITE studies.8,9 The bi-
ologics (speciﬁcally TNF inhibitors) achieved corticosteroid reduc-
tion in 75% of patients at 1 year, although this study only described
treatment outcomes in children (Table 2).13
Immunosuppression also may be used in speciﬁc diseases in
which high doses of corticosteroids are not adequate to control the
disease (e.g., mucous membrane pemphigoid, Behçet retinal
vasculitis) or in which clinical outcomes have been reported to
improve with the use of these drugs (e.g., birdshot chorioretinop-
athy). For example, immunosuppression achieved disease control
in 50e89% of patients with Behçet's disease,5,14e16 and disease
remission in 75% of patients with serpiginous choroidopathy.17 For
mucous membrane pemphigoid, immunosuppressive medications
achieved disease control in 83% of patients by 6 months, and dis-
ease remission in 91% of patients by 2 years (Table 3).3ccess, both, or remission.
g % of both achieved at 1 y Percentage or rate of remission
58 6 8% at 1 y 6
47 5 0.09/PY 5
55 7
0.32/PY 9
0.50/PY 24
63% by 2 y 9
75% by 3 y 9
91% by 2 y (MMP only) 9
77% by 4 y 26
75 13
Table 3
Effectiveness: Outcomes of immunosuppressive therapy for speciﬁc diseases.
Disease % of patients with
disease control
% of patients
in remission
% decrease in number of patients
with vision loss to 20/200
% decrease in incidence of complications
Behçet's disease 50e89% 5,14e16
Serpiginous choroidopathy 75% 17
Birdshot chorioretinopathy 82% decrease in CME 18
100% with reversal of VF loss 19
MFCPU 90% 20 83% decrease in overall complications 20
100% decrease in new CNV or optic neuropathy 21
Chronic VKH 92% 22
MMP 83% by 6 mo 3 91% by 2 y 3
CME ¼ cystoid macular edema; CNV ¼ choroidal neovascularization; MFCPU ¼ multifocal choroiditis and panuveitis; MMP ¼ mucous membrane pemphigoid; VF ¼ visual
ﬁeld; VKH ¼ VogteKoyanagieHarada syndrome.
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In addition to disease control and corticosteroid-sparing effects,
immunosuppressive medications may improve a variety of clinical
outcomes. For example, immunosuppression signiﬁcantly reduced
new-onset cystoid macular edema [relative risk (RR) ¼ 0.17; 95%
conﬁdence interval (CI) 0.05e0.64; p ¼ 0.009],18 and reversed vi-
sual ﬁeld loss19 in patients with Birdshot chorioretinitis. For pa-
tients with multifocal choroiditis and panuveitis (MFCPU), use of
immunosuppressive agents reduced the risk of posterior segment
complications by 83%, prevented risk of visual loss to the 20/200 or
worse threshold by 90%; and prevented new cases of optic neu-
ropathy and choroidal neovascularization (CNV) in contralateral
eyes of patients with unilateral optic neuropathy or CNV due to
MFCPU.20,21 In the case of chronic VogteKoyanagieHarada syn-
drome (VKH), use of immunosuppressive drug therapy was asso-
ciated with a 67% reduction of vision loss to the 20/50 threshold or
worse, and a 92% reduction of vision loss to the 20/200 threshold or
worse.22 For patients with acute VKH uveitis, addition of immu-
nosuppressive medication (speciﬁcally MMF) to corticosteroids as
ﬁrst-line therapy led to a 15% reduction in disease recurrence, a 35%
reduction in overall complications, a 36% increase in achievement
of 20/20 visual acuity, and 100% prevention of late-stage retinal
ﬁndings (sunset glow fundus).23
In comparison to corticosteroids, immunosuppressant agents
are capable of inducing medication-free remission (as opposed to
suppression). For the antimetabolites, remission rates typically
were 0.09/person-year (PY; 95% CI 0.07e0.12/PY)6 for methotrexate
and 0.09/PY (95% CI 0.06e0.14/PY) for azathioprine.5 For the alky-
lating agent cyclophosphamide, remission rates have been reported
to be between 0.32/PY and 0.50/PY annually9,24; 63% of patients
achieved remission within 2 years, and 75% of patients achieved
remission within 3 years.9 Similarly, chlorambucil has a reported
remission rate of 43% in patients with Behçet's disease uveitis over
1.5 years,25 and 77% in patients with all types of ocular inﬂamma-
tion within 4 years.26 Among patients with mucous membrane
pemphigoid, the rate of remission appeared even higher for
cyclophosphamide with a cumulative incidence of remission of 91%
at 2 years after initiation of therapy (Table 3).3
2. Short-term toxicities of immunosuppressive agents
Despite a growing literature supporting the effectiveness of
immunosuppressive drug therapy in the treatment of ocular in-
ﬂammatory disease, side effects of such therapy remain a concern.
Fortunately, recent data from both prospective and retrospective
studies of ocular inﬂammation patients support the relative safety
of immunosuppressive medications, particularly in terms of short-
term safety and tolerability. In the Multicenter Uveitis Steroid
Treatment (MUST) trial, for example, systemic adverse eventstypically associated with immunosuppression were no more com-
mon in the group randomized to systemic therapy (in which 86%
received immunosuppression) than in the group randomized to
ﬂuocinolone acetonide implant therapy, with the exception that an
increased risk of infections required antibiotics; however, this risk
was low in both groups.27 The immunosuppressant-speciﬁc risks
requiring surveillance are summarized in Table 4.
2.1. Short-term toxicities: Antimetabolites
The majority of data on the use of antimetabolites suggest a
favorable safety proﬁle, including decades of experience in non-
ocular ﬁelds (such as for methotrexate and azathioprine). Most side
effects are detectable by following established monitoring guide-
lines, are reversible with dose reduction or cessation, and only
infrequently require discontinuation of drug (Table 4).5 One sig-
niﬁcant irreversible effect of the antimetabolites is teratogenicity;
therefore, withdrawal of therapy before planned pregnancy and use
of contraception during therapy is mandatory.7
Adverse effects of methotrexate monotherapy include gastro-
intestinal intolerance, oral ulcers, hepatotoxicity, cytopenias, and
interstitial pneumonia. The SITE study reported discontinuation
due to these side effects at a rate of 0.13/PY (95% CI 0.10e0.17/PY).6
For MMF monotherapy, the SITE study reported cessation due to
side effects at a rate of 0.10/PY (95% CI 0.06e0.14/PY),7 similar to
two retrospective case series reporting discontinuation due to side
effects at rates of 0.08/PY (95% CI 0.03e0.16/PY)10 and 0.09/PY28
over 6 years of follow-up, respectively. Enteric-coated mycophe-
nolate sodium is available to help minimize gastrointestinal side
effects (the most common treatment-limiting toxicity of antime-
tabolites7) while maintaining similar immunosuppressive
beneﬁts.29
For azathioprine monotherapy, gastrointestinal symptoms
caused discontinuation at a rate of 0.06/PY (95% CI 0.03e0.10/PY)
during 2 years of follow-up.5 This was followed in frequency by
bone marrow suppression (0.03/PY; 95% CI 0.01e0.07/PY), elevated
liver enzymes (0.03/PY; 95% CI 0.01e0.06/PY), and allergic reaction
(0.01/PY; 95% CI 0.001e0.03/PY), with an overall toxicity-related
discontinuation rate of 0.16/PY (95% CI 0.11e0.22/PY).5 Rarely, a
homozygous deﬁciency of thiopurine methyltransferase (TPMT)
can result in severe decreases in leukocytes, red blood cells, and
platelets; thus, many clinicians recommend testing for TPMT ac-
tivity prior to initiating azathioprine therapy, as dose-adjustment
guidelines are available.30
2.2. Short-term toxicities: T-cell inhibitors
Of the T-cell inhibitors, cyclosporine has been the most widely
used and studied for ocular inﬂammatory diseases, although
tacrolimus and sirolimus also may be used. In the SITE study,
Table 4
Short-term side effects of immunosuppressive medications.
Medication More common side effects Rare side effects
Antimetabolites (methotrexate, mycophenolate mofetil, azathioprine) Gastrointestinal upset Hepatotoxicity
Bone marrow suppression Malaise, myalgia, fatigue
Headache
Rash
Alopecia
Teratogenicity
T-cell inhibitors (cyclosporine, tacrolimus) Renal toxicity Hepatotoxicity
Hypertension Hirsutism
Neurologic symptoms Gingival hyperplasia
Gastrointestinal symptoms (tacrolimus) Hypomagnesemia
Hyperglycemia (tacrolimus)
Alkylating agents (cyclophosphamide, chlorambucil) Bone marrow suppression Ovarian suppression
Cystitis, hematuria (cyclophosphamide) Testicular atrophy azoospermia, male sterility
Alopecia
Nausea, vomiting
TNF inhibitors (inﬂiximab, adalimumab, etanercept) Infusion/hypersensitivity reactions
Autoantibody formation
Interferons Flu-like symptoms (almost universal) Psychological disturbances
Mild leukopenia Arthralgia, myalgia
Thrombocytopenia
Fever, nausea, headache
Thyroiditis
Alopecia
Hepatotoxicity
Lymphocyte inhibitors (rituximab, abatacept) Infusion/hypersensitivity reactions Leukopenia
Granulocytopenia
Gamma-globulin decrease
TNF ¼ tumor necrosis factor.
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PY (95% CI 0.05e0.09/PY).8 Renal toxicity and hypertension were
the most frequent side effects, occurring at rates of 0.02/PY (95% CI
0.01e0.04/PY) and 0.02/PY (95% CI 0.009e0.03/PY), respectively.8
Discontinuation of cyclosporine was statistically signiﬁcantly
associated with increasing age; compared with patients aged
18e39 years, discontinuation for toxicity was 3.25 times more
common in patients aged 55e64 years, and was 5.66 times more
common in patients aged > 65 years (overall p ¼ 0.0005).8
Although no data on treatment with cyclosporine for ocular in-
ﬂammatory diseases during pregnancy are available, in a transplant
pregnancy cohort, no excess malformations were observed in
women receiving cyclosporine during pregnancy.31
A previous retrospective case series evaluating tacrolimus for
ocular inﬂammation also found a low discontinuation rate due to
toxicity (0.13/PY), predominantly due to noncardiovascular and
nonrenal effects such as neurologic symptoms (e.g., tremor, par-
esthesias), gastrointestinal symptoms, hyperglycemia, insomnia,
and headache.32 Rarely, tacrolimus causes irreversible toxicity to
pancreatic beta cells leading to type 1 diabetes mellitus. Sirolimus
has been associated with cytopenias, hypercholesterolemia, ar-
thralgias, extremity edema, and impaired wound healing.33
2.3. Short-term toxicities: Alkylating agents
The alkylating agents cyclophosphamide and chlorambucil
typically are used for very severe inﬂammatory disease due to the
high-toxicity risk associated with these drugs. For example, the
SITE study reported discontinuation of cyclophosphamide therapy
at an overall rate of 0.39/PY (95% CI 0.31e0.49/PY),9 substantially
higher than rates of antimetabolites or T-cell inhibitors observed in
the same cohort. The most commonly reported side effects were
leukopenia (0.20/PY; 95% CI 0.14e0.27/PY), thrombocytopenia
(0.016/PY; 95% CI 0.003e0.046/PY), anemia (0.04/PY; 95% CI
0.015e0.075/PY), and cystitis/blood in the urine (0.07/PY; 95% CI0.04e0.12/PY).9 Other studies have shown the bone marrow sup-
pression of cyclophosphamide to be dose dependent and revers-
ible, with older individuals being more susceptible.34,40
The adverse effects of chlorambucil therapy are similar to those
of cyclophosphamide, with bone marrow suppression being the
most common toxicity.34 Both cyclophosphamide and chlorambucil
can cause alopecia, sterility, and embryotoxicity.26,33 Bladder
toxicity is not associated with chlorambucil therapy.
2.4. Short-term toxicities: Biologics
Many of the side effects of TNF-alpha inhibitors are sufﬁciently
mild to not require discontinuation. These include autoantibody
formation16,34; limited treatment in volume-sensitive individuals
(such as those with low cardiac output), due to intravenous
administration of the medication; and infusion reactions such as
local erythema at the injection site, atopic dermatitis, ﬂushing, rash,
hypertension, fever, and fatigue.16 Subcutaneously delivered bi-
ologics may be associated with injection site pain as well. These
effects generally do not lead to discontinuation of therapy. Some of
these agents appear to be safe to use during pregnancy.35
Rituximab has side effects, which are usually mild, transient,
and do not result in discontinuation of therapy. Hypersensitivity
reactions including hypotension, local erythema, cough, laryngeal
edema, and infusion-related rigors occur occasionally.36 A meta-
analysis of patients with lymphoma taking rituximab showed
increased risk of severe leukopenia (RR ¼ 1.24; 95% CI 1.12e1.37)
and granulocytopenia (RR ¼ 1.07; 95% CI 1.02e1.12), although this
did not result in higher infection risk.37
Dose-dependent ﬂu-like symptoms from interferon-alpha
treatment are expected, but usually do not require discontinua-
tion. In a retrospective study of interferon-alpha treatment in pa-
tients with severe uveitis due to Behçet's disease, discontinuation
due to toxicity occurred in 9.4% of patients during nearly 5 years of
follow-up.14 In addition to ﬂu-like symptoms, mild leukopenia (>
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none.14 Uncommon ﬁndings during treatment included ﬁbromy-
algia, depression, hair loss, thrombocytopenia, headache, mild
hepatotoxicity, thyroiditis, fever, and nausea.
The more concerning side effects reported with biologic therapy
such as increased risk of infections (including tuberculosis) and the
potential risk of cancer with use of these agents are discussed in the
following sections.
3. Infection risk with immunosuppressive agents
Increased infection risk is a frequent concern when using
immunosuppressive medications for ocular inﬂammation, and data
regarding this risk are summarized in Table 5. In the MUST trial, a
higher risk of infections requiring a drug prescriptionwas observed
in the systemic therapy group (systemic corticosteroids plus
immunosuppression in 86% of patients) than in the implant group
(0.60/PY vs. 0.36/PY, p¼ 0.034). However, these typically were mild
infections and as such, it is unclear to what extent the difference
reﬂected an increased likelihood of prescribing drugs for mild in-
fections in patients known to be taking immunosuppressive drugs
(as both participants and clinicians were unmasked) rather than a
true difference in infection incidence.27
Existing data from the SITE Cohort Study reported no observed
opportunistic infections in patients treated with MMF, metho-
trexate, or azathioprine monotherapy (with or without systemic
corticosteroids).5e7 This conﬁrmed previous evidence showing no
increase in infection risk associated with MMF monotherapy.27 The
SITE study also showed no increased infection risk associated with
T-cell inhibitors,38 consistent with previous studies reporting no
association of cyclosporine or tacrolimus monotherapy with
increased risk of serious infections.34
These results for monotherapy are reassuring, but patients
sometimes require multiagent therapy. The combination of an
antimetabolite with a T-cell inhibitor such as cyclosporine is a
common approach, because the drugs have different toxicity pro-
ﬁles and have been used together for other conditions such as
transplantation.34 In some transplant cohorts, the combination of
MMF with cyclosporine (with or without corticosteroids) has been
associated with a nonsigniﬁcant increase in opportunistic in-
fections compared with either agent alone (Table 5)39; however,
infection risk was substantially lower in an ocular inﬂammation
cohort in which only two patients developed major infections
while taking MMFecyclosporine combination therapy.
In contrast to antimetabolites and T-cell inhibitors, cyclophos-
phamide has been associated with opportunistic infections in
ocular inﬂammation patients, leading to discontinuation in 3.0%
(95% CI 1.2e7.1%) of patients in the 1st year, at a rate of 0.03/PY over
3 years of follow-up (95% CI 0.0084e0.061).9 Infections includedTable 5
Infection and malignancy risk of immunosuppressive medications for ocular inﬂammato
Medication Increased infection
with or without co
Antimetabolites None (2þþ)
T-cell inhibitors None (2þþ)
Combined therapy (antimetabolite and T-cell inhibitor) Mild increase (2þ
Alkylating agents Increase (2þþ)
Biologics
TNF inhibitors Mild increase (1þ
Interferons None (2þþ)
Rituximab None (1þþ)
TNF ¼ tumor necrosis factor.
a Medication may interact with other factors to increase cancer risk.Pneumocystis jirovecii pneumonia leading to death in one (0.5%)
patient, who had been managed according to standard guidelines
but had not taken the recommended Pneumocystis prophylaxis
with trimethoprim/sulfamethoxazole. These ﬁndings are consis-
tent with (but less extreme than) results of a previous randomized
controlled clinical trial of 50 patients with Wegener's gran-
ulomatosis, which reported infections in 70% of patients receiving
cyclophosphamide, including 30% who developed P. jirovecii
pneumonia.40 Substantial granulocytopenia (absolute neutrophil
count < 1000 cells/mL) associated with cyclophosphamide can in-
crease the risk of bacterial infections, particularly sepsis. To
decrease the risk of infections and sepsis, many clinicians tempo-
rarily discontinue cyclophosphamide for white blood counts below
2500 cells/mL, followed by downward dose adjustment.34 This
practice may explain the lower risk of infection observed in the
ocular inﬂammation cohort.9
The most common infection sites in patients taking biologics are
the respiratory tract, skin and soft tissues, and urinary tract.41 Anti-
TNF therapy is associated with increased risk of infection with
intracellular pathogens, such asMycobacterium tuberculosis, Listeria
monocytogenes, and Legionella pneumophila.42 A meta-analysis of
TNF inhibitors in 369 patients with Behçet's disease reported
tuberculosis reactivation in four patients, and opportunistic in-
fections in 10 patients (including P. jirovecii pneumonia,
L. pneumophila pneumonia, cryptococcal meningitis, varicella zos-
ter infection, cytomegalovirus colitis, forearm cellulitis, and bac-
terial endocarditis).16 A meta-analysis of adults with rheumatoid
arthritis taking inﬂiximab or adalimumab reported a statistically
signiﬁcant higher risk [odds ratio (OR) ¼ 2.0; 95% CI 1.3e3.1) of
serious infections during 22e54 weeks of follow-up, but the ab-
solute risk was low (0.036% with anti-TNF therapy vs. 0.017% with
placebo).43 Such a low absolute risk probably does not represent a
clinically important constraint on the use of these agents for ocular
inﬂammation, but clinicians should bear in mind that signiﬁcant
infection does occur occasionally.
The risk of severe infection due to rituximab therapy also ap-
pears low.36,37,44 Although a randomized, double-blind, placebo-
controlled, dose-ranging trial of rituximab reported serious infec-
tion that was 0.015/PY higher than in the placebo group, the ab-
solute rates for both groups were low (0.052/PY vs. 0.037/PY,
respectively) and no tuberculosis or opportunistic infections
occurred in either group.36 Furthermore, two meta-analyses of
patients with lymphoma treated with rituximab showed no sta-
tistically signiﬁcant increases in the risk of severe infection (deﬁned
as life threatening, or requiring hospitalization or intravenous
antibiotics).37,44
Infection risk with interferon treatment has also been reported
to be low, with no increased risk of opportunistic infections for
either interferon-alpha29 or interferon-gamma.45ry disease.
risk with medication,
rticosteroids (evidence grade)
Increased cancer risk with medication
(evidence grade)
None (2þ to 2þþ)
None a (2 to 2þþ)
)
Increase a (2þþ to 3)
þ) None (2þ)
None (2)
None (2)
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Immunosuppression has been thought to increase the risk of
skin, mucosal, and lymphoproliferative cancers. Proposed mecha-
nisms include susceptibility to infection with oncogenic infectious
agents, interrupted immune surveillance of malignant cells, and
damage to DNA (alkylating agents) or to DNA metabolism (anti-
metabolites).46 However, most of these observations are from
transplant studies, and may not apply to ocular inﬂammation pa-
tients. Incidences of cancer associated with immunosuppressive
drugs used in ocular inﬂammatory disease are summarized in
Table 5.
Antimetabolites appear to have a relatively low risk of clinically
important carcinogenicity. Azathioprine has been studied in pa-
tients with rheumatoid arthritis, inﬂammatory bowel disease, and
multiple sclerosis, and consistently has shown no increased risk of
malignancy except for sporadic reports of post-transplant lym-
phoproliferative disorder (PTLD)-like cases,46 which do not occur
more often in treated than in nontreated patients (RR¼ 1.27, 95% CI
0.03e8.20).47 Methotrexate also has shown no increased cancer
risk in several cohorts with a variety of diseases.46 Although rare
PTLD-like cases have been reported, a large observational study
following 19,591 rheumatoid arthritis patients over 89,710 PY
found no increased lymphoma risk with methotrexate therapy,48
suggesting that PTLD-like cases are rare in nontransplant pa-
tients. Observational studies of MMF in the post-transplant setting
have found a signiﬁcantly reduced risk of PTLD, improved survival
of patients with PTLD, and a lower cancer risk when MMF is
compared with alternative regimens,46 which has contributed to a
preference for this drug over alternatives in transplant patients.
Studies of T-cell inhibitors, derived from transplant cohorts,
show the increased malignancy risk typical of those cohorts.
However, this risk is not necessarily applicable to nontransplant
cohorts.46,49 For example, a cohort of rheumatoid arthritis patients
showed no increased malignancy risk due to cyclosporine treat-
ment.50 Thus, in the absence of these treatments or of an organ
transplant, such as in uveitis patients, cyclosporine likely would not
confer a higher cancer risk.46
By contrast, alkylating agents are associated with higher ma-
lignancy risk. Several studies have shown that cyclophosphamide
increases incidence of leukemia, lymphoma, and skinmalignancies,
as well as bladder cancer due to the accumulation of acrolein (a
carcinogenic metabolite) in urine.46 Bladder cancer risk appears to
be dose and/or duration dependent, is higher in smokers, and can
be mitigated by intravenous or oral hydration to prevent acrolein
buildup.51 Chlorambucil has been linked to development of cuta-
neous malignancies, lymphoma, and leukemia, but not with
bladder cancer.46
The majority of reports on cancer risk with TNF inhibitors are
favorable. Seven large observational studies of TNF inhibitors for
rheumatoid arthritis, with nearly 100,000 PY of follow-up, showed
no increased malignancy risk,48,52e58 except for nonmelanotic skin
cancer in one analysis (OR ¼ 1.5 vs. no anti-TNF therapy).59 Results
in a Crohn's disease cohort also found no increased cancer risk.60
Regarding lymphoma speciﬁcally, a large observational database
of 19,591 patients (approximately 89,710 PY of follow-up) with
rheumatoid arthritis showed no increased lymphoma risk with
anti-TNF therapy61; in addition, a meta-review of lymphoma risk in
patients with rheumatoid arthritis found no clear association be-
tween lymphoma and anti-TNF therapy.62 By contrast, a meta-
analysis of TNF inhibitors in 5014 patients with rheumatoid
arthritis in clinical trials showed a 3.3-fold higher cancer risk over
22e54weeks of follow-up, but this was theorized to be the result of
accelerated diagnosis of pre-existing cancers given the short period
during which the difference appeared.43Published results from clinical trials have shown no increased
risk of malignancy due to rituximab therapy (RR ¼ 1.05, 95% CI
0.76e1.42).63 These ﬁndings were similar to an observational
cohort study of 186 rheumatoid arthritis patients reporting no
increased cancer risk due to rituximab treatment.64 For this reason,
rituximab is sometimes considered the ﬁrst choice in patients with
current or previous history of cancer in whom anti-TNF is
contraindicated.
Regarding interferon-alpha therapy, a retrospective study of
patients with Behçet-associated uveitis found no increase in ma-
lignancy with interferon-alpha over nearly 8 years of follow-up,65
as did a systematic literature review of 338 patients with ocular
and systemic manifestations of Behçet's disease.66
5. Mortality risk with immunosuppressive agents
Data on mortality risk of immunosuppressive drugs for patients
with ocular inﬂammatory disease were evaluated in the SITE
Cohort Study.
Antimetabolites as a class were not associated with increased
overall mortality [adjusted hazard ratio (aHR) ¼ 1.08, 95% CI
0.86e1.37) or cancer-related mortality (aHR ¼ 0.89, 95% CI
0.54e1.48). Azathioprine, methotrexate, and MMF individually
were not associated with increased overall or cancer-related mor-
tality. Similarly, T-cell inhibitors as a classdor cyclosporine indi-
viduallyddid not increase overall mortality (aHR ¼ 0.81, 95% CI
0.59e1.11) or cancer-related mortality (aHR ¼ 0.78, 95% CI
0.38e1.59). The latter observation was consistent with a retro-
spective cohort study showing no increased mortality risk in pa-
tients with rheumatoid arthritis treated with cyclosporine.50
Alkylating agents as a class were not associated with signiﬁ-
cantly increased overall mortality (aHR ¼ 1.17, 95% CI 0.85e1.61) or
cancer-related mortality. However, statistical power for the latter
outcome was limited and available data did show a trend toward
increased risk (aHR ¼ 1.74, 95% CI 0.91e3.32), which was similar to
the increased cancer risk observed in other cohorts and also
consistent with previous reports showing a dose-dependent in-
crease in cancer-related mortality due to cyclophosphamide.24,67
These risks generally restrict the use of these agents to the most
serious cases of ocular inﬂammatory disease.
Several well-powered rheumatologic cohort studies of TNF in-
hibitors have found no increased mortality risk.49,52e54,56 By
contrast, the SITE Cohort Study showed signiﬁcant increases in
overall mortality (fully aHR ¼ 1.99, 95% CI 1.00e3.98) and cancer
mortality (HR ¼ 3.83, 95% CI 1.13e13.01) in association with TNF
inhibitors. Individual risk ratios for etanercept and inﬂiximab were
similar in magnitude, but nonsigniﬁcant due to sample size and
follow-up time.
Long-term data are more limited on rituximab. A recent analysis
of 500 patients with pemphigus vulgaris treated with rituximab
therapy showed no increase in mortality risk.68 However, because
B-cell depletion can last for  18 months after rituximab therapy,
there is reasonable concern that future data will show an increase
in infection-related mortality.69 Further research is needed to
determine the risk of mortality with interferon therapy for eye
disease.
6. Conclusion
In summary, increasing evidence supports the effectiveness
and safety of using immunosuppressive drug therapy as treat-
ment for ocular inﬂammatory diseases. The antimetabolites and
the biologics, in particular, appear to offer the best balance be-
tween effectiveness and safety and pose excellent alternatives to
long-term high-dose corticosteroid therapy. Immunosuppressive
D.M. Hornbeak, J.E. Thorne / Taiwan Journal of Ophthalmology 5 (2015) 156e163162drugs should be used to control inﬂammation when corticoste-
roids fail to do so, to prevent corticosteroid-induced toxicity, and
to treat high-risk uveitis syndromes unresponsive to corticoste-
roids alone.
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